TABLE 3.

TEAEs occurring in ≥15% of patients overall by dose level

	Any grade							Grade ≥3
	7 mg QD n = 3	12 mg QD n = 3	20 mg QD n = 3	35 mg QD n = 8	60 mg QD n = 7	80 mg QD n = 3	Overall n = 27	Overall n = 27
TEAE	Number (%) of patients
Platelet count decrease	0 (0.0)	1 (33.3)	2 (66.7)a	2 (25.0)	6 (85.7)a	2 (66.7)	13 (48.2)b	5 (18.5)a
Decreased appetite	1 (33.3)	1 (33.3)	1 (33.3)	3 (35.7)	1 (14.3)	2 (66.7)	9 (33.3)	0 (0.0)
Anemia	1 (33.3)	1 (33.3)	2 (66.7)	3 (37.5)	1 (14.3)	0 (0.0)	8 (29.6)	4 (14.8)
Nausea	1 (33.3)	1 (33.3)	0 (0.0)	3 (37.5)	3 (42.9)	0 (0.0)	8 (29.6)	0 (0.0)
AST increase	0 (0.0)	1 (33.3)	1 (33.3)	4 (50.0)	2 (28.6)	0 (0.0)	8 (29.6)	1 (3.7)
Fatigue	0 (0.0)	1 (33.3)	2 (66.7)	2 (25.0)	1 (14.3)	1 (33.3)	7 (25.9)	0 (0.0)
ALT increase	0 (0.0)	1 (33.3)	0 (0.0)	2 (25.0)	3 (42.9)	0 (0.0)	6 (22.2)	2 (7.4)
Headache	0 (0.0)	0 (0.0)	1 (33.3)	2 (25.0)	1 (14.3)	2 (66.7)	6 (22.2)	0 (0.0)
Abdominal pain	1 (33.3)	1 (33.3)	1 (33.3)	1 (12.5)	0 (0.0)	1 (33.3)	5 (18.5)	0 (0.0)
Constipation	0 (0.0)	1 (33.3)	1 (33.3)	2 (25.0)	0 (0.0)	1 (33.3)	5 (18.5)	0 (0.0)
Disease progression	0 (0.0)	1 (33.3)	2 (66.7)	2 (25.0)	0 (0.0)	0 (0.0)	5 (18.5)	5 (18.5)
Weight decrease	0 (0.0)	0 (0.0)	2 (66.7)	2 (25.0)	1 (14.3)	0 (0.0)	5 (18.5)	0 (0.0)
Dizziness	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (28.6)	2 (66.7)	5 (18.5)	0 (0.0)

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; QD, once daily; TEAE, treatment-emergent adverse event.

^aIncludes thrombocytopenia (n = 1).

^bIncludes thrombocytopenia (n = 2).